Concurrent glucocorticoid taper enables reintroduction of alectinib after drug-induced rash
Abstract
With the rise of precision medicine in oncology, targeted therapies are increasingly used to treat cancers with actionable mutations. Alectinib, a selective anaplastic lymphoma kinase (ALK) inhibitor, is currently approved as a first-line therapy option for patients with metastatic ALK-rearranged non–small cell lung cancer.1,2 Alectinib–associated cutaneous eruption, most commonly described as a morbilliform or macular and papular erythematous rash, is a known adverse effect of alectinib. Although the majority of rashes are classified as grade 1 to 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events, rare grade ≥ 3 reactions have been reported and may require treatment interruption or discontinuation.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
HER2/EGFR in Cancer Research
Chronic Myeloid Leukemia Treatments
Publication details
- Journal / source
- JAAD Case Reports
- Publisher
- Elsevier BV
- Volume
- 71
- Pages
- 57–62
- Publication date
- 13 February 2026
- Language
- EN